Seeking Alpha·16h ago
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call TranscriptRigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
Rigel Pharmaceuticals has undergone a dramatic financial transformation, with equity surging from -$31.7M in 2024Q1 to $425.4M by 2026Q2, driven by a $268.1M tax benefit and improved operations. The company's asset-light model (CapEx near zero) and high gross ...
Price trend, volume and key moving averages
Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.65-29.4% vs $0.92 | $81M+1.0% vs $80M |
Q3 2026 Aug 4, 2026 | $0.88+903.9% vs $0.09 | $79M+42.4% vs $55M |
Q2 2026 May 5, 2026 | $0.44-40.5% vs $0.74 | $59M-5.7% vs $62M |
Q2 2026 Mar 3, 2026 | $1.14-14.3% vs $1.33 | $70M+1.6% vs $69M |
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1.46 per share a year ago.
Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 million VEPPANU™ (vepdegestrant) became commercially available in mid-August and generated $6.6 million in initial net product sales for the third quarter The Phase 1b study of R289, Rigel's dual IRAK1/4 inhibitor, in patients with lower-risk MDS is ongoing and Rigel expects to select the recommended Phase 2 dose by the end of 2026 Oral presentation at the ASH Annual Meeting in December will feature updated data from the ongoing Phase 1b study of R289 in patients with lower-risk MDS Updated 2026 Outlook: Total revenues of approximately $290 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $260 million and contract revenues from collaborations of approximately $35 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.
Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Three poster presentations will highlight data for TAVALISSE ® (fostamatinib disodium hexahydrate) in patients with chronic ITP and wAIHA SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b clinical study of R2891, a potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed or refractory (R/R) to prior therapies will be presented in an oral session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday, December 12, 2026.
Benchmark RIGL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Rigel Pharmaceuticals, Inc. (RIGL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $45.71 | $845.73M | 2.35 | 64.15% | 124.72% | 185.94% | — | |
| $7.89 | $413.07M | -1.74 | -92.84% | -80.67% | -14.98% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $15.57 | $1.53B | -2.67 | 20.13% | -71.78% | — | — | |
| $122.96 | $14.58B | 48.03 | 37.55% | 24.86% | 180.63% | — | |
| $65.67 | $5.45B | 8.44 | 114.51% | -9.17% | — | — |
Rigel Pharmaceuticals, Inc. (RIGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Rigel Pharmaceuticals, Inc. (RIGL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jul 1, 2026·SEC
Jun 17, 2026·SEC
Get notified when RIGL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rigel Pharmaceuticals, Inc. (RIGL) stock FAQ — growth, dividends, profitability & financials explained
Rigel Pharmaceuticals, Inc. (RIGL) reported $276.8M in revenue for fiscal year 2025. This represents a 2981% increase from $9.0M in 1999.
Rigel Pharmaceuticals, Inc. (RIGL) grew revenue by 64.1% over the past year. This is strong growth.
Yes, Rigel Pharmaceuticals, Inc. (RIGL) is profitable, generating $321.9M in net income for fiscal year 2025 (124.7% net margin).
Rigel Pharmaceuticals, Inc. (RIGL) has a return on equity (ROE) of 185.9%. This is excellent, indicating efficient use of shareholder capital.
Rigel Pharmaceuticals, Inc. (RIGL) generated $79.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
